Navidea Biopharmaceuticals (NYSE:NAVB) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the stock.

Navidea Biopharmaceuticals Stock Performance

NYSE:NAVB opened at $0.00 on Wednesday. Navidea Biopharmaceuticals has a 1-year low of $0.00 and a 1-year high of $0.13. The firm has a market capitalization of $10,008.40, a PE ratio of 0.00 and a beta of 1.20.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.